Jazz Pharmaceuticals plc (NASDAQ: JAZZ) filed an order in New Jersey’s District Court stating that it had dismissed the last of the patent claims against the company’s cannabis epilepsy drug Epidiolex. Jazz acquired the company GW Pharmaceuticals which had developed Epidiolex for the treatment of rare pediatric epilepsy conditions Dravet Syndrome and Lennox-Gastaut.
Jazz began the fight in 2023 accusing companies of violating its patents. The companies included Teva Pharmaceuticals, Apotex Inc., Padagis US LLC, InvaGen Pharmaceuticals and its parent Cipla USA Inc., API Pharma Tech LLC, Lupin Ltd., Alkem Laboratories Ltd., Taro Pharmaceutical Industries Ltd., Ascent Pharmaceuticals Inc., MSN Pharmaceuticals Inc., Zanara Pharma Private Ltd. and Biophore Pharma Inc. It didn’t take long for companies to begin dropping out of the case as they reached settlements with Jazz.
Apotex looks to be the final company to reach an agreement with Jazz which had accused the company of infringing on 20 Jazz patents. Jazz claimed Apotex was asking the FDA for approval for a generic version of Epidiolex.
Despite some pushback from the other drug companies, ultimately their attempts failed and Apotex was the last company to settle. The order stated that the case was,
hereby dismissed without prejudice, and without costs or attorneys’ fees to the Parties.
The success of Epidiolex made it a target for competitors. Green Market Report wrote in November that Epidiolex, accounted for $251.5 million in revenue for the company’s third quarter, up from $213.7 million the same quarter a year ago. For the past nine months ending in September, Epidiolex has generated $697 million in sales – an increase of 15% over the previous year. Epidiolex, which is now available in 35 countries, was second in sales only to Xywav, Jazz’s sleep aid drug, which sold $388.4 million in the quarter.
The company also announced in December that it achieved positive results for its drug when treating tuberous sclerosis complex (TSC) a rare genetic condition. The condition causes mostly benign tumors to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs and is a leading cause of genetic epilepsy.
2294000-2294695-https-ecf-njd-uscourts-gov-doc1-119122186850 [[{“value”:”The success of Epidiolex prompted several companies to attempt to create generic versions.
The post Jazz Pharmaceutical wraps up Epidiolex patent claims appeared first on Green Market Report.”}]] Read More
